On April 25, 2008, the drug's manufacturer Actavis Toyota, LLC, a U.S. subsidiary of Actavis Group, voluntarily initiated a nationwide recall of Digitek oral tablets of all strengths. Digitek is sold and distributed by two companies, Mylan Pharmaceuticals, Inc. under a "Bertek" label and by UDL Laboratories, Inc. under a "UDL" label.

The recall occurred after it was discovered that as a result of a manufacturing defect, tablets may have been sold in the U.S. market with double the thickness of the normal sized tablets. These flawed Digitek tablets may contain as much as twice the active ingredient. This could mean that patients who take the defective tablets may be exposed to twice the strength of the prescribed dosage.

DrugSettlement.com has created a portal at http://drugsettlement.com/drugs/digitek/facts  to provide information to consumers and their families who may have been the victims of Digitek overdoses. An overdose of Digitek can cause in digitalis toxicity, characterized by nausea, vomiting, dizziness, low blood sugar, cardiac instability and bradycardia. Deaths have also been reported. Actavis Totowa has received numerous reports of illnesses and injuries due to patients who may have taken the defective tablets.

Our affiliated attorneys are currently investigating claims on behalf of victims and their families, for those who died or who suffered from the effects of Digitek. If you or a loved one has suffered an injury or any of the side effects listed above while taking these drugs, make sure to contact the experienced, and knowledgeable DrugSettlement.com lawyers at http://drugsettlement.com